anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1451237 Cleaning teeth STANDARD OIL CO 28 Sept 1973 [3 Oct 1972] 45437/73 Heading A5R [Also in Division C4] Dental floss comprises a yarn or filamentary material coated with a matrix of a natural or synthetic resilient wax or of polyethylene, polyethylene glycol, chlorosulphonated polyethylene; a polybutene-based rubber, an isoprene based rubber, a copolymer of butadiene and isoprene, styrene or acrylonitrile, polyvinyl or polyvinylidene chloride, a polyester or polyether-based elastomer, a silicone rubber or a polyurethane, or a mixture of these, and, as polishing agent, an oxide, silicate, carbide, boride, carbonate, phosphate, sulphide, or nitride of calcium, magnesium, silicon, aluminium, iron, titanium, zinc, tungsten, zirconium, tin, sodium or potassium or a mixture of two or more of these. The polishing agent may be present in a ratio of 1:5 to 5:1 compared with the matrix. The yarn may be of cotton, silk, linen, nylon, polyester or acrylic fibres. The matrix may be applied to the yarn or filament by passing through a bath of the polymer solution, and then through a die or wire coater. The polishing agent may then be applied by passing the still wet filament through a solid or fluid bed of the particles, lengths of the floss may be left uncoated at regular intervals. Alternatively the particles may be mixed with the matrix material before application to the filament.
On day 1, patients received daily oral doses of prednisone 20 mg along with daily oral placebo doses to in a double-dummy manner to maintain the blind. On day 15, partial and complete responders continued in the study and tapered their steroid treatment according to standard care. Non-responders were discontinued from the study.
PURPOSE: A composition and functional food containing Aurantii Immatri Pericarpium organic solvent extract is provided to effectively prevent and treat prostate cancer. CONSTITUTION: A composition for preventing and treating prostate cancer contains organic solvent extract of Aurantii Immatri Pericarpium as an active ingredient. The organic solvent is ethanol. The ethanol extract is prepared at 50°C for 24 hours. The composition contains pharmaceutically acceptable carrier or diluent. A functional food for preventing prostate cancer contains the extract and sitologically acceptable food additive.
Approximately 2.6% of Americans age 18 and older, or 5.7 million people, suffer from bipolar disorder. The manic and depressive episodes associated with bipolar disorder prevent normal functioning in individuals with the disorder, but functional impairment can occur even when bipolar disorder is in remission. Previous research indicates that this impairment in stable individuals with bipolar disorder is linked to neurocognitive deficits, such as problems with memory and attention. The drug extended release galantamine increases the level of acetylcholine, a neurotransmitter important for memory, available in the brain. This drug has already been approved by the FDA to treat neurocognitive impairment in Alzheimer's disease patients. This study will examine whether administering the drug to individuals with bipolar disorder who are in remission can also reduce their neurocognitive deficits and improve the quality of their life. The study will also examine the safety of the drug for use in the obsessive-compulsive disorder population.

Participation in this study will last about 18 weeks and will involve six study visits. Each of the first two visits will include 2 hours of clinical, physical, and self-report tests, the first for screening and the second to establish physical and mental health baseline measurements. Participants will then be randomly assigned to receive either galantamine or placebo daily for 16 weeks, and they will be provided with enough of the assigned pill to last until the next visit. Half hour visits on Weeks 4, 8, and 12 will consist of psychological self-report tests and interviews, clinical assessment of side effects from the drug, and the determination by the examining doctor and participant whether to increase, decrease, or maintain the same level of the drug. Participants will also be given enough of the drug to last until the next visit. The final visit, on Week 16, will last 2 hours and will consist of the same tests administered at the baseline visit in addition to the neuropsychological tests administered at the screening visit. The full range of tests will measure physical health, verbal memory, mental flexibility, attention, life impairment, and life satisfaction.
PROBLEM TO BE SOLVED: To effectively utilize Cassia angustifolia Vahl. stems which slightly but still contains a pharmaceutically active ingredient and which have been uselessly discarded as wastes, thus reducing the discharge of wastes. SOLUTION: This food composition for drinking is obtained by homogeneously mixing the roasted or thermally dried product of Cassia angustifolia Vahl. stems with the roasted or thermally dried product of a raw material. The roasted or thermally dried product of the Cassia angustifolia Vahl. stems is prepared by finely grinding or pulverizing the Cassia angustifolia Vahl. stems not containing sites capable of being utilized as medicines and subsequently roasting or thermally drying the treated product. The roasted or thermally dried product of the raw material is prepared by finely grinding or pulverizing a raw material capable of being utilized for health foods and subsequently roasting or thermally drying the ground or pulverized product.
Systems and methods can support generation of a full-thickness, human skin organ from tissue culture expanded cells. Human dermal and epidermal progenitor cells can be isolated from human tissues. Isolated cells may be cultured as epidermal cells while other isolated cells may be separately cultured as dermal cells. The cultured epidermal cells and dermal cells may be combined for co-culturing. The co-cultured cells may be suspended within a slurry. The co-cultured cells may be implanted onto a recipient organism for generation of a full-thickness skin organ comprising fully cycling hair follicles, adipose tissue, and other skin organ structures.
This group will be composed of 22 patients with shoulder dysfunction post liver donation. Patients will receive neural mobilization techniques in addition to conventional physical therapy program. Exercises will be applied for 3 times a week for 4 consecutive weeks.
Skin wound healing will become a pressing and difficult problem following injury to the skin structure. Persistent wounds, in particular, become more vulnerable to bacterial infections, which can contribute to persistent skin inflammation. Therefore, it is critical to create a wound dressing that promotes wound healing while also being antimicrobial. In the present work, a multifunctional biological activity hydrogel formed by enzymatic cross-linking was developed by introducing graphene oxide (GO) and lactoferrin to gelatin hydrogel. Furthermore, by incorporating lactoferrin, the composite hydrogels exhibit excellent in vitro antibacterial and biocompatibility. According to cell experiments, the LTF-GO/Gel hydrogel can improve wound healing by enhancing L929 cell migration. Interestingly, under near-infrared light, LTF-GO/Gel hydrogel increases the generation of singlet oxygen (1O2) and hydroxyl radical (-OH), making the hydrogel system excellent antioxidant and antibacterial capabilities, these results demonstrate that the LTF-GO/Gel hydrogel has clinical promise as a wound dressing for wound healing. In vivo experiments unequivocally establish the capacity of the LTF-GO/Gel hydrogel to expedite wound healing and mitigate inflammation. This hydrogel, therefore, harbors immense potential for applications in wound healing.
Multiple doses of LY3502970 administered orally. Some participants will also receive atorvastatin and simvastatin or midazolam administered orally.
Patient will be implanted with the medical device under investigation, LymphoPilot, through a surgical procedure performed in loco-regional or general anesthesia. Lymphedema outcomes will be monitored for 8 weeks after implantation and compared to baseline values before device implantation. Safety data will be collected throughout the study.
PCT No. PCT/GB93/00034 Sec. 371 Date Aug. 11, 1994 Sec. 102(e) Date Aug. 11, 1994 PCT Filed Jan. 8, 1993 PCT Pub. No. WO93/13803 PCT Pub. Date Jul. 22, 1993A method for producing a drug system which is a reversible gelled matrix with entrapped drug. The gel is made by combining a polysaccharide, such as dextran, a polymer of glucose, with a natural macromolecule, such as the lectin, concanavalin A, with binding sites for monomers of the polysaccharide. The drug is released in response to exposure of the matrix to free carbohydrate containing the monomer of the polysaccharide for which the natural macromolecule binds.
Participants were instructed to place the capsule near the root of the tongue and fold the string in their mouths, leaving approximately 20 cm of string outside, with a blue mark on the string right at the lips. The capsule was then swallowed with water, and the end of the string was held out of the mouth. Participants were then asked to slowly drink 150-200 mL of 50°C water in approximately 2 minutes to allow the capsule to dissolve so that the sponge mesh inside was released. The device was then slowly withdrawn up the esophagus by pulling the string. The retrieved and expanded cell collection material was put in preservative fluid (Froeasy Technology, Nanjing, China) and transferred to the cytology laboratory at room temperature.
PURPOSE:To provide the titled compsn. which is useful for tooth paste, shampoo, etc., and exhibits color change clearly in a predetermined time containing an immobilized dye obtd. by fixing a water-soluble anionic dye to a water-insoluble cationic polymer and an ionic surfactant in a specified form. CONSTITUTION:100pts.wt. water-insoluble cationic polymer (a) having a surface area of 0.1-500m<2>/g and a particle size of 0.1-50mu (e.g., a bisphenol/ epichlorohydrin type epoxy resin/piperazine polycondensate) as a dye-fixing substrate is added to 0.5-20pts.wt. water-soluble anionic dye (b) (e.g., Red No.2). A solvent such as water, methanol, etc., is added thereto and the mixture is mixed under acidic conditions to ionically bond them to each other and the product is dried and crushed to obtain an immobilized dye (A). The component A is blended with an ionic or semipolar nonionic surfactant (B) (e.g., sodium laurylsulfate) in a weight ratio of A to be of 0.1/10-10/1 in such a form that the components A and B undergo an exchange reaction by an external action, e.g., by encapsulating the component A and blending the same.
PROBLEM TO BE SOLVED: To obtain the subject composition improved in transdermal absorbability and useful as a pharmaceutical preparation of local administration type, by formulating a higher unsaturated aliphatic alcohol in a diclofenac sodium- dissolved composition. SOLUTION: This composition is obtained by formulating a diclofenac sodium- dissolved composition comprising (A) pref. about 0.1-5.0wt.% diclofenac sodium, (B) pref. about 10-96wt.% water and (C) pref. about 0.01-10wt.% a fatty acid dialkylolamide with (D) pref. 0.1-5wt.%, based on the whole base, a higher unsaturated aliphatic alcohol (pref. oleyl alcohol). The formulation of this composition is pref. ointment, cream, lotion, emulsion, cataplasm or patch.
AIM: JNK pathway-associated phosphatase (JKAP) regulates T cell-mediated immunity and inflammation, which are involved in atherosclerosis pathogenesis. This study investigated the effects of JKAP on T-helper (Th) cell polarization, inflammation, and atherosclerotic progression.
METHODS: Serum JKAP levels were measured in 30 patients with coronary heart disease (CHD) and 30 controls. CHD blood naïve CD4+ T cells were acquired, followed by JKAP overexpression and knockdown with or without treatment with PD98059 (ERK inhibitor) or BAY-11-7082 (NF-κB inhibitor) in vitro. CD4+ T-cell conditional JKAP ablation mice were established in vivo, followed by the construction of an atherosclerosis model.
RESULTS: JKAP was reduced and negatively correlated with the Gensini score, CRP, Th1 cells, Th17 cells, and proinflammatory cytokines in patients with CHD. In vitro, JKAP overexpression suppressed Th1 and Th17 cell differentiation and proinflammatory cytokines, whereas JKAP knockdown exerted the opposite effect; however, JKAP modification did not affect Th2 cell differentiation. Interestingly, JKAP negatively regulated the ERK and NF-κB pathways; meanwhile, the PD98059 and BAY-11-7082 treatments repressed Th1 and Th17 cell differentiation, and attenuated the effect of JKAP knockdown on these indices. In vivo, conditional CD4+ T-cell JKAP ablation increased Th1 and Th17 cell polarization in the spleen, lymph node, blood, and/or aortic root. Furthermore, CD4+ T-cell conditional JKAP ablation exaggerated atherosclerotic lesions in the aorta, elevated CD4+ cell infiltration and proinflammatory cytokines in the aortic root, and activated the ERK and NF-κB pathways in the aortic root.
CONCLUSION: JKAP ablation facilitates atherosclerosis progression by promoting Th1 and 17 polarization and inflammation through regulation of the ERK and NF-κB pathways.
Recently, the newer forms of intubating devices combining video technologies were introduced. The fiberoptic stylets are useful instrumentations especially for difficult airways and limited neck mobilizations.The OptiScope® is a semi-rigid videostylet designed for endotracheal intubation. While using the device, visualization of the airway might be obscured by the secretions during its insertion. The deterioration of the view leads to intubation failure, resulting in multiple intubation attempts, longer intubating time and desaturation.Therefore, while using the Opticoscope®, proper antisialagogic preparation will be helpful.

Total 78 patients scheduled for general anesthesia aged 20-65 years and Anesthesiologists physical status (ASA) class 1 or 2 will be included. The obese patients (BMI\>30) and expected difficult intubation will be excluded. The sample size was estimated based on the preliminary study. With a type Ⅰ error estimate(α) of 0.05 at 80% power, we estimated that 30 patients in each group, or 60 in total, were needed. Considering the drop-out rate of 30%, the total sample size were 78 in total. The patients will be randomly allocated to the glycopyrrolate group(G) and the control group(C). The group-G will received intramuscular glycopyrrolate 0.005mg/kg injection 1 hour before the surgery. For the group-C glycopyrrolate will not be administered. Intubation will be conducted with the OptiScope®. While intubating, the degree of the secretion will be evaluated through the OptiScope® and graded excellent, good, poor and unacceptable according to the dryness and the visualization of the vocal cord. When the vocal cord was seen without secretions, it was stated 'Excellent'. 'Good' was graded when secretions existed without the need for suctioning to visualize the vocal cord. When there were secretions and needed suctioning to clear the view, the subjects were rated 'Poor'. When intubation was failed due to poor visualization of the vocal cord despite the suctioning of the secretion, it was graded 'Unacceptable'. If the intubation is not available within 1 minute, the intubation will be done with the laryngoscope. The time to intubate will be checked by the assist anesthesiologist. The definition of the 'intubation time' is the time between the introduction of the OptiScope® into the mouth and the confirmation of the proper intubation with capnographic wave.The baseline vital signs including systolic blood pressure, mean arterial pressure, diastolic blood pressure and heart rate will be measured before the intubation and 1,3 and 5 minutes after the intubation.

The collected data will be compared with the independent t-test or Mann-Whitney-Wilcoxon test for the continuous variables. Χ2 test and Fisher's exact test will be performed for the categorical variables. Significant level will be set at 0.05.
PURPOSE: To produce an ideal substitute tooth crown excellent in load and impact resistances, biocompatibility, aesthetic properties, cutting properties, coloring processability, reactivity, etc., with saliva by mixing a rigid resin with a specific compound. CONSTITUTION: This substitute tooth crown is obtained by mixing a rigid resin with hydroxyapatite, then curing and molding the resultant mixture. The molar ratio of Ca to P in the hydroxyapatite is preferably 1.5-2.0. An ultrafine powder prepared by baking the hydroxyapatite at <800 deg.C or a granular substance obtained by baking the hydroxyapatite at >=800 deg.C is preferably used. Furthermore, the ultrafine powder preferably has <=5μm particle diameter and the granular substance is a dense one having >=75% relative density. The granular substance is preferably a crushed, a needlelike or fibrous substance having 1-500μm particle diameter. The ultrafine powder or granular substance is preferably pretreated with a carboxylic acid or a polycarboxylic acid or a salt thereof.
FIELD: medicine, oncology, biotechnology. SUBSTANCE: vegetable-microbial-phage an antitumor agent is prepared by prolonged multistep fermentation of the parent raw that is celandine or biomass of other symbiotic plants. The first stage of fermentation is carried out for 5-6 weeks at temperature that eliminates biomass drying or decaying followed by its milling; the second stage - at 32-36 C for 10-14 days; the third stage - at 28-35 C for 3-4 months. After the first stage of fermentation fermented raw is boiled for 1.5-2 h. Liquid phase is separated after the second stage of fermentation. Filtration is carried out after liquid phase separation and after forth stage of fermentation filtration is carried out followed by boiling. The obtained agent shows antitumor activity and can be used in veterinary science also. EFFECT: improved method of preparing.
A large number of children with cGVHD have to deal with many years of a disfiguring and painful chronic illness with the side effects of long term steroid use. The number of stem cell transplants done in children is only growing given that we are now transplanting patients with a variety of nonmalignant disorders and given the use of alternative donor sources. The broad categories of limited and extensive cGVHD are recognized by clinicians, but are not particularly useful in clinical practice. Since cGVHD may involve almost every organ system adn since cGVHD constitutes a waxing and waning nature, cGVHD makes clinical management very difficult and complicated. Currently, there is a symptoms scale used in the adult population for measuring symptom burden for adults with cGVHD. This scale is called the "Lee Symptoms Scale". The purpose of this project is to develop a scale that is similar in design to the Lee Scale, but it is specifically designed to measure the burden of cGVHD in the pediatric population
Objective: To assess the clinical features and CT diagnostic characteristics of Branchio-Oto-Renal or Branchio-Oto Syndrome. Methods: The temporal CT findings and clinical features observations of 13 patients with Branchio-Oto-Renal Syndrome (BORS) or Branchio-Oto Syndrome(BOS) confirmed by genetic testing were retrospectively analyzed. There were 8 males and 5 females, aged from 1 to 39 years, with a median age of 9 years, in which 3 pairs (6 cases) were parent-child relationship. Results: All of 13 cases had hearing loss and preauricular fistula, 11 cases accompanied by 2nd branchial fistulas. There were 20 ears of mixed hearing loss, 3 ears of sensorineural hearing loss, and 2 ears of conductive hearing loss. The mutation point of gene testing was located in EYA1 in 12 cases and SIX1 in 1 case. Twenty ears showed gradually narrowing of the diameter of basal turn, with hypoplasia in the second turn and aplasia in apical turn. There were irregular wall of vestibule and horizontal semicircular canal in 10 ears,widened vestibular in 7 ears, and vestibular fusion with horizontal semicircular canal in 3 ears. Three ears had an enlarged vestibular aqueduct, 8 ears showed enlargement of internal auditory canal. Seventeen ears had adhesion of malleolus to tympanic cavity. Six ears could not measured the incudostapedial joint angle by reason of tympanic inflammatory cover, 3 ears could not show incudostapedial joint, and 8 ears showed the incudostapedial joint angle more than 122°. Six ears showed poor oval window, and 1 ear had poor round window. Eighteen ears showed distended eustachian tube, and accompanied by tympanic or mastoiditis in 11 ears. Anterolateral shift of tympanum was found in 22 ears, 17 ears had low middle cranial fossa, and 3 ears had stenotic external auditory canal. Conclusions: Cochlear dysplasia, ossicular chain malformation and distended eustachian tube comprise the characteristic CT signs of BOS/BORS, which possesses versatile and complex CT findings. Temporal CT can accurately assess the important structures such as cochlea, ossicles, vestibule, semicircular canal, vestibular aqueduct and internal auditory canal. Combing with the clinical characteristics of bilateral, mixed hearing loss, preauricular fistula and branchial fistula can provide valuable information for early diagnosis and treatment.
The present invention provides methods for making, delivering and using formulations that combine a therapeutically active agent(s) (such as for example a Rho antagonist(s)) and a flowable carrier component capable of forming a therapeutically acceptable matrix in vivo (such as for example tissue adhesives), to injured nerves to promote repair and regeneration and regrowth of injured (mammalian) neuronal cells, e.g. for facilitating axon growth at a desired lesion site. Preferred active agents are known Rho antagonists such as for example C3, chimeric C3 proteins, etc. or substances selected from among known trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane compounds or Rho kinase inhibitors. The system for example may deliver an antagonist(s) in a tissue adhesive such as, for example, a fibrin glue or a collagen gel to create a delivery matrix in situ. A kit and methods of stimulating neuronal regeneration are also included.
Disclosed is a system (101) and a method (300) for providing mental health or behavioural health services. The system (101) includes a data generation module (210) and a natural language processing module (206), which work together to capture and store user data related to their medical treatment. The data generation module (210) is responsible for storing various types of data pertaining to the user, such as their medical history and treatment information. The natural language processing module (206) captures the user's responses during treatment and transcribes them into written notes. This allows for easier understanding and sharing of the information within the system (101). The system (101) and the method (300) has potential applications for delivering mental health services through various channels, including interactive computer terminals and mobile applications. This could lead to increased accessibility, convenience, scalability, and potentially improved mental health outcomes for individuals and communities.